VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

IMS 2022 | An insight into the heterogeneity of SMM and how genetic subtypes impact risk of disease progression

Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, shares some insights into the heterogeneity of smoldering multiple myeloma (SMM) and challenges in diagnosing patients. Dr Ghobrial also explains how genomic and epigenetic information can help clinicians better understand a patient’s risk of progression to multiple myeloma. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter